Soraia de Oliveira Simião

Ms. Soraia de Oliveira Simião

Pharmacy, Federal University of Paraná, Curitiba, Paraná, Brazil
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NGNaomi Gerzvolf
Naomi Gerzvolf
Soraia de Oliveira SimiãoSoraia de Oliveira Simião
Soraia de Oliveira Simião
LCLuiza Stolz Cruz
Luiza Stolz Cruz
RMRafaela Cirillo de Melo
Rafaela Cirillo de Melo
NKNajeh Maissar Khalil
Najeh Maissar Khalil
Luana Mota FerreiraLuana Mota Ferreira
Luana Mota Ferreira
Background/Objectives: Cutaneous melanoma is a potent neoplasm whose advancement is linked to catecholamine-induced angiogenesis through β-adrenergic receptors. Propranolol (PROP), a non-selective β-blocker, holds potential in oncology, but its systemic side effects restrict its viability. This study aims to nanoencapsulate PROP in Eudragit RL®100 polymeric nanocapsules for topical melanoma treatment. Methods: Nanocapsules were created through interfacial deposition of preformed polymer and characterized in terms of particle size, zeta potential, pH, drug content, and encapsulation efficiency. In vitro evaluations include release profile, antioxidant activity, bioadhesiveness, hemolysis, cytotoxicity, and antitumor effect on melanoma cells. Additionally, migration assays were conducted. Results: The nanocapsules displayed an acidic pH, an average size of 151 nm, and a positive zeta potential. An encapsulation efficiency of 81% was achieved, even with the hydrochloride form of the drug. The release profile exhibited sustained release of PROP, showcasing enhanced antioxidant activity in the nanoencapsulated form. The formulations also exhibited significant bioadhesion with mucin and an in vitro hemolysis rate over 50%, attributed to the cationic polymer and surfactants present. Moreover, in the cell viability assays, the NC-PROP formulations significantly reduced melanoma cell viability. In the migration assay, both the nanocapsules with and without the drug significantly inhibited cell migration, supporting the potential therapeutic benefits of these formulations. Conclusions: The nanoencapsulation of PROP in Eudragit RL®100 presents a viable strategy for topical treatment of cutaneous melanoma, enhancing release duration and reducing systemic effects. The assessments indicated distinct physical properties and substantial therapeutic potential.

10 February 2026 in Microbial Pathogenesis
Verified
Journal Article
Closed access
LALaiene Antunes Alves
Laiene Antunes Alves
Soraia de Oliveira SimiãoSoraia de Oliveira Simião
Soraia de Oliveira Simião
LALaís Salvador Do Amaral
Laís Salvador Do Amaral
RLRaul Edison Luna Lazo
Raul Edison Luna Lazo
MSMarcel Henrique Marcondes Sari
Marcel Henrique Marcondes Sari
Luana Mota FerreiraLuana Mota Ferreira
Luana Mota Ferreira